Ezogabine (retigabine)

Carl E. Stafstrom, Seden Grippon, Peter Kirkpatrick

Research output: Contribution to journalArticlepeer-review

Abstract

Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).

Original languageEnglish (US)
Pages (from-to)729-730
Number of pages2
JournalNature Reviews Drug Discovery
Volume10
Issue number10
DOIs
StatePublished - Oct 2011
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Ezogabine (retigabine)'. Together they form a unique fingerprint.

Cite this